UBS Group cut shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a neutral rating in a research report report published on Friday. They currently have $18.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on SCMP. B. Riley lowered shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $18.00 price target for the company. in a report on Tuesday, December 26th. ValuEngine raised shares of Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a report on Sunday, December 31st. Maxim Group lowered shares of Sucampo Pharmaceuticals to a hold rating in a report on Monday, January 1st. Leerink Swann reissued a market perform rating and issued a $15.00 price target on shares of Sucampo Pharmaceuticals in a report on Tuesday. Finally, Mizuho reissued a neutral rating and issued a $18.00 price target (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $21.58.

Sucampo Pharmaceuticals (SCMP) traded down $0.10 during trading hours on Friday, hitting $18.05. 5,272,846 shares of the stock were exchanged, compared to its average volume of 3,798,216. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.20. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market capitalization of $846.44, a PE ratio of -5.49, a P/E/G ratio of 5.10 and a beta of 1.45.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. Sucampo Pharmaceuticals’s quarterly revenue was up 5.9% compared to the same quarter last year. analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.13% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Krensavage Asset Management LLC grew its holdings in Sucampo Pharmaceuticals by 0.6% during the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after acquiring an additional 16,570 shares during the period. LSV Asset Management grew its holdings in Sucampo Pharmaceuticals by 1.9% during the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after acquiring an additional 44,000 shares during the period. Point72 Asset Management L.P. acquired a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth $21,989,000. Vanguard Group Inc. grew its holdings in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after acquiring an additional 189,561 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after acquiring an additional 15,528 shares during the period. 65.29% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/sucampo-pharmaceuticals-scmp-downgraded-to-neutral-at-ubs-group/1797420.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.